According to the report, the Size of the Middle East & Africa Rhinoconjunctivitis Market is valued at USD xx Million in 2022 and is poised to reach USD xx Million by 2028, to grow at a CAGR of xx.x% during the forecast period 2023 to 2028.
The high incidence of rhinoconjunctivitis will be a crucial factor in the market's growth during the study period. An article published in the Journal of Allergy and Therapy mentions that rhinoconjunctivitis is one of the most common reasons for allergies for hospital visits. Other publications also report that most asthma patients also suffer from this disease, and more than 21.23% of patients with rhinoconjunctivitis also have concomitant asthma.
The rate of progress has increased dramatically in adults and children due to allergies. Consumption of foods mainly stored in refrigerators, industrialization, and air pollution are also responsible for the increase in prevalence, according to a study published in Allergy, Asthma & Immunology Research Journal. In addition, more than 63% of children with rhinoconjunctivitis also presented eye symptoms, often poorly recognized.
An article published in the World Allergy Organizations Journal suggests that no specific data is available to study this disorder's changing trends. In a report published by the Health Authority, a considerable increase in the prevalence of rhinoconjunctivitis has been observed during the changes of the season. The government is focusing on increasing awareness about this disease to limit its growth. Likewise, ongoing research and development and increased knowledge about various allergic reactions and their preventions will support the market growth in the MEA region.
Certain restrictions and barriers will limit the growth of the MEA rhinoconjunctivitis market. Factors include the expiration of patents, lack of awareness, healthcare policies, and competition from generic drugs. Moreover, the growing preference for complementary and alternative therapies are potential constraints hampering the overall growth.
This research report on the Middle East & Africa Rhinoconjunctivitis Market has been segmented and sub-segmented into the following categories.
By Treatment:
By Country:
Geographically, the Middle East & Africa Rhinoconjunctivitis Market is projected to grow at a decent CAGR due to the large population and an increasing number of rhinoconjunctivitis cases. In addition, other factors like the growing awareness, supportive government initiatives, expansion of advanced health infrastructure, and growth of the R&D sector will be responsible for the positive change seen in this region.
Due to the high prevalence of this disease, the government encourages the need for comprehensive and sustained programs for early diagnosis and appropriate management of asthma and allergy among adults and children.
The UAE Rhinoconjunctivitis Market is predicted to reach a decent CAGR due to the increasing awareness, supportive government initiatives, expansion of advanced health infrastructure, and growth of the R& D sector will be responsible for the positive change seen in this region.
The Saudi Arabia Rhinoconjunctivitis Market is estimated to grow significantly due to the increasing availability of healthcare facilities. The high rate of seasonal allergies will support the market growth in this region.
The South African rhinoconjunctivitis Market is the fastest-growing market. It is anticipated to grow at a high CAGR during the period, which is attributed to the availability of key market players, poor health habits, overexposure to allergic substances, and excessive tobacco consumption will increase the prevalence rate of rhinoconjunctivitis.
KEY MARKET PLAYERS
Key Market Companies dominating the Middle East & Africa Rhinoconjunctivitis Market Profiled in the Report are Johnson & Johnson Inc., Merck & Co., Inc., GlaxoSmithKline, Sanofi Adiga Life Sciences Inc.,
Related Reports
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 1200
Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM
Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: [email protected]
Reports By Region